Company / Cash & Equivalents
InspireMD, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.9M
FY2025
5-year range
$4.6M / $18.9M
FY2021-FY2025
Trend
-52.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $3M in FY2016 to $19M in FY2024.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of -6.7%.
Declined from $10M to $9M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +24.5%
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -6.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 52.7% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.42 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.9M | -52.7% |
| FY2024 | $18.9M | +96.2% |
| FY2023 | $9.6M | +108.1% |
| FY2022 | $4.6M | -61.4% |
| FY2021 | $12.0M | -5.1% |
| FY2020 | $12.6M | +129.3% |
| FY2019 | $5.5M | -41.2% |
| FY2018 | $9.4M | +24.9% |
| FY2017 | $7.5M | +130.8% |
| FY2016 | $3.3M | -48.3% |
As of FY2025 · SEC 10-K Annual Filings · Last checked Jun 28, 2026